The Moment that KRAS Mutation Started to Evolve into Precision Medicine in Metastatic Colorectal Cancer.
Division of Epigenomics, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan. tushijim@ncc.go.jp.
Toshikazu
T
Ushijima
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Takayuki
T
Yoshino
D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D006801:Humans; D009154:Mutation; D061206:Neoplasm Micrometastasis; D057285:Precision Medicine / Q000379:methods*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D016283:Proto-Oncogene Proteins p21(ras) / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000378:metabolism
C117307:KRAS protein, human; D047428:Protein Kinase Inhibitors; D016283:Proto-Oncogene Proteins p21(ras)